Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

A large study that retrospectively analyzed the visual outcomes and rate of development of neovascular age-related macular ...

Astellas Pharma seeks Japanese conditional approval of avacincaptad pegol intravitreal solution to treat geographic atrophy: Tokyo Thursday, February 6, 2025, 09:00 Hrs [IST] Aste ...

(RTTNews) - Astellas Pharma Inc. (ALPMY) Wednesday announced the submission of a New Drug Application or NDA in Japan for Conditional Approval of Avacincaptad Pegol intravitreal solution or ACP for ...

Astellas Pharma has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare seeking ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

In this Healio Video Perspective from Retina 2025, Roger A. Goldberg, MD, MBA, discusses the role of multimodal imaging in geographic atrophy in the era of complement inhibitors.Imaging confirms the ...

Belite Bio is a biotech firm specializing in innovative therapies for retinal degenerative eye diseases with high unmet needs ...

Ministry of Health, Labour and Welfare to evaluate ACP as potential first and only treatment for patients with geographic atrophy (GA) secondary ...

Australia's Therapeutic Goods Administration has approved the use of a new and first treatment for geographic atrophy - a disease which causes severe ...